![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sinopharm to Begin Phase 3 Trial of its COVID-19 Vaccine Candidate in Peru
Sinopharm to Begin Phase 3 Trial of its COVID-19 Vaccine Candidate in Peru
![Sinopharm_Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/Sinopharm_Logo.png?t=1597974966&width=430)
August 21, 2020
Sinopharm has announced that it will launch another phase 3 trial of its experimental COVID-19 vaccine candidate, this time in Peru, following a greenlight from the Peruvian health regulator.
The state-owned Beijing-based company is currently conducting a late-stage trial in the United Arab Emirates that is studying two formulations of the vaccine in 15,000 participants and a separate phase 3 trial in Bahrain that will enroll 6,000 participants.
Sinopharm previously announced that its experimental COVID-19 vaccine was found to be safe and generated high levels of antibodies in a phase 1/2 trial in China.
Upcoming Events
-
21Oct